329 related articles for article (PubMed ID: 18591458)
1. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
Michea L; Villagrán A; Urzúa A; Kuntsmann S; Venegas P; Carrasco L; Gonzalez M; Marusic ET
Hypertension; 2008 Aug; 52(2):295-300. PubMed ID: 18591458
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Martín-Fernández B; de las Heras N; Miana M; Ballesteros S; Valero-Muñoz M; Vassallo D; Davel AP; Rossoni LV; Cachofeiro V; Lahera V
Exp Physiol; 2012 Jun; 97(6):710-8. PubMed ID: 22327331
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
5. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T
Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H
Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775
[TBL] [Abstract][Full Text] [Related]
7. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Tatsumoto N; Yamada S; Tokumoto M; Eriguchi M; Noguchi H; Torisu K; Tsuruya K; Kitazono T
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F967-79. PubMed ID: 26336165
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.
Bostick B; Habibi J; DeMarco VG; Jia G; Domeier TL; Lambert MD; Aroor AR; Nistala R; Bender SB; Garro M; Hayden MR; Ma L; Manrique C; Sowers JR
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1126-35. PubMed ID: 25747754
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
Wang H; Shimosawa T; Matsui H; Kaneko T; Ogura S; Uetake Y; Takenaka K; Yatomi Y; Fujita T
J Hypertens; 2008 Jul; 26(7):1453-62. PubMed ID: 18551023
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
[TBL] [Abstract][Full Text] [Related]
12. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
Lister K; Autelitano DJ; Jenkins A; Hannan RD; Sheppard KE
Cardiovasc Res; 2006 Jun; 70(3):555-65. PubMed ID: 16533503
[TBL] [Abstract][Full Text] [Related]
13. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
Kuster GM; Kotlyar E; Rude MK; Siwik DA; Liao R; Colucci WS; Sam F
Circulation; 2005 Feb; 111(4):420-7. PubMed ID: 15687129
[TBL] [Abstract][Full Text] [Related]
15. AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
Marques-Neto SR; Ferraz EB; Rodrigues DC; Njaine B; Rondinelli E; Campos de Carvalho AC; Nascimento JH
Cardiovasc Drugs Ther; 2014 Apr; 28(2):125-35. PubMed ID: 24258356
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction.
Bender SB; DeMarco VG; Padilla J; Jenkins NT; Habibi J; Garro M; Pulakat L; Aroor AR; Jaffe IZ; Sowers JR
Hypertension; 2015 May; 65(5):1082-8. PubMed ID: 25712719
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade.
Martín-Fernández B; de las Heras N; Valero-Muñoz M; Ballesteros S; Yao YZ; Stanton PG; Fuller PJ; Lahera V
PLoS One; 2014; 9(10):e111104. PubMed ID: 25353961
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptors mediate cardiac remodelling in morphine-dependent rats.
Mesripour A; Iyer A; Brown L
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):75-80. PubMed ID: 22304485
[TBL] [Abstract][Full Text] [Related]
19. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
Loan Le TY; Mardini M; Howell VM; Funder JW; Ashton AW; Mihailidou AS
Hypertension; 2012 Jun; 59(6):1164-9. PubMed ID: 22508833
[TBL] [Abstract][Full Text] [Related]
20. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
